Company profile: OSE Immunotherapeutics
1.1 - Company Overview
Company description
- Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
Products and services
- Tedopi: A clinical-stage, neoepitope-based cancer vaccine in Phase 3 for non-small cell lung cancer patients resistant to checkpoint inhibitors, produced for immuno-oncology applications
- BI 765063 (OSE-172): A receptor-targeted monoclonal antibody against SIRPα for advanced solid tumors, developed in partnership with Boehringer Ingelheim, engineered for immuno-oncology therapeutic products
- OSE-127 (Lusvertikimab): A receptor-specific monoclonal antibody targeting the interleukin-7 receptor in Phase 2 clinical trial for ulcerative colitis, developed for auto-immune disease therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OSE Immunotherapeutics
Quell Therapeutics
HQ: United Kingdom
Website
- Description: Provider of engineered regulatory T cell (Treg) therapies for solid organ transplant and autoimmune diseases. Develops QEL-001 to prevent liver transplant rejection without lifelong immunosuppression and, with AstraZeneca, engineered Treg therapies for Type 1 Diabetes and Inflammatory Bowel Disease. Offers a modular platform using proprietary technologies to enhance Tregs, target specific antigens, and direct them to specific body targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quell Therapeutics company profile →
OrganOx
HQ: United Kingdom
Website
- Description: Provider of normothermic machine perfusion technology for donor livers via OrganOx metra, enabling functional assessment and preservation for up to 24 hours. Offerings support evaluation of liver function prior to transplantation, provide more flexible transplant logistics and surgery scheduling, and support complex or lengthy surgeries by extending preservation time.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrganOx company profile →
SQI Diagnostics
HQ: Canada
Website
- Description: Provider of medical systems and diagnostics leveraging proprietary multiplexing, miniaturization, and automation; offerings include RALI-Dx IL-6 Severity Triage for COVID-19, rapid mobile PCR testing, Sofia SARS Antigen FIA, Sofia2 Flu+SARS Antigen FIA, QuickVue At-Home OTC COVID-19 test, and the TORdx LUNG test under development to assess donor lung health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SQI Diagnostics company profile →
Verici Dx
HQ: United States
Website
- Description: Provider of RNA signature-based diagnostics for kidney transplant patients, offering pre- and post-transplant prognostic tests—Clarava to predict early rejection risk and Tutivia to assess post-transplant rejection risk—and RNA Signature Tests that provide insights into immune response and transplant prognosis, while tracking patient records and the patient journey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verici Dx company profile →
TransMedics
HQ: United States
Website
- Description: Provider of organ preservation technology and clinical service solutions for transplantation, offering OCS Heart, OCS Lung, and OCS Liver systems that keep donor organs functional for viability assessment and transport; the National OCS Program with technology, clinical services, and training; and the OCS Lung Solution for flushing, storage, and transportation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TransMedics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OSE Immunotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OSE Immunotherapeutics
2.2 - Growth funds investing in similar companies to OSE Immunotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OSE Immunotherapeutics
4.2 - Public trading comparable groups for OSE Immunotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →